The B7/CD28 family has profound modulatory effects in immune responses and constitutes important targets for the development of novel therapeutic drugs against human diseases. Here we describe a new CD28 homolog (CD28H) that has unique functions in the regulation of the human immune response and is absent in mice. CD28H is constitutively expressed on all naive T cells. Repetitive antigenic exposure, however, induces a complete loss of CD28H on many T cells, and CD28H-negative T cells have a phenotype of terminal differentiation and senescence. After extensive screening in a receptor array, a B7-like molecule, B7 homolog 5 (B7-H5), was identified as a specific ligand for CD28H. B7-H5 is constitutively found in macrophages and could be induced on dendritic cells. The B7-H5/CD28H interaction co-stimulates human T cell growth and cytokine production, selectively via an AKT-dependent signaling cascade. Our study identifies a novel co-stimulatory pathway regulating human T cell responses.
Introduction
Current research supports the notion that T cell activation and tolerance is orchestrated by the co-signaling network 1, 2, 3 . The B7/CD28 family molecules play critical and unique roles among co-signaling molecules, and the B7/CD28 axis was the first to be identified and the most extensively studied ligand/receptor complex for T cell co-stimulation 4, 5, 6 . Among its various effects on T cells, CD28 has been recognized as a major co-stimulatory receptor specialized in priming pan naïve T cells, and promoting both T cell division and cytokine production, especially interleukin 2 (IL-2) in secondary lymphoid organs 7 . CD28 signaling prevents T cell anergy, the unresponsiveness status of T cells to antigen challenge 8, 9 . Moreover, survival of activated T cells can be enhanced by CD28 co-stimulation, in part by the up-regulation of the survival factor, Bcl-xL 10 . CTLA-4, the counterpart for CD28, is critical for the maintenance of T cell tolerance, because disruption of its interaction with B7-1 and B7-2 leads to broad and profound lymphocyte infiltration in the peripheral and lymphoid organs 7 .
The important role of the B7/CD28 family in the modulation of immune response has been highlighted by three biologics drugs approved by the FDA and several promising agents in clinical trials for the treatment of human diseases. Infusion of CTLA4-Fc recombinant fusion protein Abatacept or Belatacept have been shown to be beneficial for the patients with rheumatoid arthritis or kidney transplantation rejection, respectively 11, 12 . Ipilimumab (Yervoy), a CTLA-4 monoclonal antibody (mAb) with the capacity to block its coinhibitory function, systemically activates T cells, which leads to enhanced antitumor immunity and therefore a survival benefit in 10-15% patients with advanced metastatic melanoma 13 . More recently, a phase I/II trial of PD-1 mAb demonstrated an objective clinical response in approximately 1/3 of the patients with advanced non-small cell lung cancer, kidney cancer, and melanoma with minimal toxicity [14] [15] [16] .
In this study, we describe a new receptor-ligand interaction in the B7/CD28 family, between CD28H and B7-H5. CD28H is constitutively expressed on naïve T cells while its ligand B7-H5 is found broadly in professional antigen-presenting cells (APCs) and in peripheral organs. The interaction of B7-H5/CD28H has profound co-stimulatory functions in human T cell responses both in vitro and vivo. Because this interaction is absent in mice, our findings warrant reassessment of the knowledge obtained from mouse models of lymphocyte cosignaling.
Results

Identification and characterization of CD28H
An extensive genome-wide search was performed to identify genes that are both preferentially expressed on T cells and homologous to CD28. Through this search we discovered a new human gene previously called transmembrane and immunoglobulin domain containing 2 (TMIGD2) (gene ID 126259). No function has been designated for this gene. Therefore we renamed it CD28 homolog (CD28H) to reflect its close relationship with CD28. The human CD28H gene locates on chromosome 19q13.3, and it consists of five exons and spans about 10.2 kilobases (Figure 1a ). The CD28H gene encodes a putative single transmembrane protein, which is composed of a single immunoglobulin variable-like (IgV) domain, one transmembrane domain, and a long intracellular domain (Figure 1b) . Alignment of the amino acid sequence of CD28H to other CD28 family members indicates that CD28H shares over 10% identity with CD28, CTLA, ICOS and PD-1 (Supplementary Figure S1a) . Phylogenic tree analysis further reveals that CD28H is closer to CD28 than PD-1 in amino acid similarity (Figure 1c ). CD28H seems to be conserved in zebra fish, guinea pig, cow and chimpanzee because all these species have CD28H orthologs and inferred protein-coding sequences (Supplementary Figure S1b) . However, mouse and rat do not have the coding gene for CD28H, though there are traces of CD28H gene fragments present in their genomes.
PCR analysis of human tissue cDNAs indicated that the CD28H transcript was preferentially enriched in lymphoid organs (Figure 1d ). The thymus and spleen had the highest levels of CD28H mRNA. In addition, peripheral blood lymphocyte (PBL) and liver also contained abundant CD28H transcript. We generated a monoclonal antibody (mAb) against human CD28H. The specificity of CD28H mAb was verified by its binding to CD28H transfectants, but not HEK293T cells transfected with other CD28 family members (Supplementary Figure  S2a) . Thymus and tonsil tissues contained a significant number of cells that stained positive for CD28H (Figure 1e ). Most immature CD4-CD8-double-negative (DN) thymocytes did not express surface CD28H. However, thymocytes in the CD4+CD8+ double-positive (DP) stage were CD28H-positive, as were the CD4+ or CD8+ single-positive (SP) cells from the thymus (Supplementary Figure S3) . We also analyzed CD28H expression in the peripheral blood mononuclear cells (PBMCs) of healthy human donors using flow cytometry. No detectable surface CD28H was found on B cells. The majority of natural killer (NK) cells, defined as CD56+ or CD16+ cells, constitutively expressed high levels of CD28H. Similarly, a large portion of CD3+ T cells from the PBMCs of the healthy donors constitutively expressed CD28H (Figure 1f ).
T cell activation leads to loss of CD28H
Further examination of CD28H expression on adult human T cell subsets by flow cytometry revealed that both CD4+ and CD8+ αβT cell subsets contained a similar percentage of T cells constitutively expressing CD28H (Figure 2a ). In contrast, virtually all γδT cells were CD28H-negative. Virtually all T cells from human cord blood, presumably naïve T cells, expressed high levels of CD28H (Supplementary Figure S4) . We further examined CD28H expression on subsets of human CD8+ T cells based on CCR7 and CD45RA expression 17 . All naive T cells (Tn, CD45RA+CCR7+) constitutively expressed CD28H (Figure 2b ). About half the T cells with central memory (CD45RA-CCR7+) and effector memory (CD45RA-CCR7−) phenotypes were CD28H positive. The majority of CD45RA+ effector memory (T EMRA ) cells (CD45RA+CCR7−), presumably terminally differentiated effector T cells, loss their CD28H expression 17, 18 . Similar findings were observed in CD4+ T cell subsets (Supplementary Figure S5a) . CD28H-negative T cells purified from PBMCs did not contain CD28H transcript, suggesting that CD28H expression on T cells is controlled in transcription level (Supplementary Figure S5b) . We further stained T cells for CD28H expression together with various T cell surface markers. CD28H-negative T cells were higher in side scatter (SSC), and most of them expressed CD45RO but not CD45RA (Supplementary Figure S5c) . In addition, the expression of activation-induced molecules like PD-1 were increased whereas the levels of CD62L and CD27 were reduced in CD28H-negative cells 19, 20 . Consistently, the CD28H-negative T cells comprised the population prior to the secretion of effector cytokines and lytic molecules upon activation (Supplementary Figure S5d) . Similarly, most effector cytokine-producing CD4+ T helper cells or FoxP3+ CD4+ T regulatory (T reg ) cells did not express CD28H (Supplementary Figure S5e) .
One possible cause of the loss of CD28H expression on antigen-experienced T cells is repetitive antigen stimulation. To test this, we purified naïve (virtually all CD28H-positive) or CD28H-negative T cells from fresh PBMCs, and stimulated them with anti-CD3 plus anti-CD28 in the presence of IL-2. Full T cell activation was achieved in four days as demonstrated by the high levels of CD69 expression and the loss of CD62L. CD28H-positive T cells maintained 100% of their CD28H expression throughout 4 days' culture (Supplementary Figure S6a and Figure 2c ). Activated T cells were rested for 3 days and restimulated on day 7. A small population of T cells started to lose CD28H on day 10. On day 14 the CD28H-negative T cell population increased to 34% (Figure 2c ). In addition, CD28H mRNA was not detectable on those newly generated CD28H-negative T cells (Supplementary Figure S6b) . On the other hand, when CD28H-negative T cells were activated, none of those T cells gained CD28H expression during the 14 day period of stimulation. Together, these results suggest that repetitive stimulations induce the irreversible loss of CD28H expression on naïve T cells.
The loss of CD28H on T cells upon cell activation was also confirmed in vivo. When naïve human T cells were transferred into immunodeficient NOD-SCID Il2rg −/− (NSG) mice, human T cells proliferated vigorously responding to xenogeneic antigens in mice 21 accompanied with progressive loss of CD28H: T cells started to lose CD28H on day 7 and more than half of the transferred human T cells had lost CD28H on day 10 and nearly all T cells were CD28H-negative on day 28 ( Figure 2d ).
Persistent immune activation causes loss of CD28 expression in human T cells, which represent a group of later-stage differentiated T cells 22 . We co-stained human CD8+ T cells with CD28H and various surface molecules, which are associated with human T cell senescence [23] [24] [25] [26] . Almost all T cells with senescent phenotype (CD7lowCD27-CD28-CD57+) were exclusively CD28H-negative (Supplementary Figure S7a) . We labeled purified CD28H+ naive and CD28H-negative T cells with CFSE, and assessed their proliferative capacity to TCR signaling. Though CD28H+ naive T cells proliferate vigorously, virtually no cell division was detected in CD28H-negative T cells in response to the same concentration of anti-CD3 (Supplementary Figure S7b) . To exclude the possibility that the slower dividing of CD28H-negative T cells is caused by a small population of internal suppressive T cells (for instance, FoxP3+ T reg cells Supplementary Figure S5e) , we labeled whole PBMCs with CFSE and tested their response to anti-CD3 within 7 day, when the majority of T cells do not change CD28H expression ( Figure 2c ). As predicted, the most actively dividing T cells are CD28H+ cells for both CD4+ and CD8+ T cells, suggesting that, in response to TCR signal, CD28H-expressing cells are far better proliferators than CD28H-negative cells (Supplementary Figure S7c) . In addition, CD28H-negative T cells generated by activation exhibited more terminal-differentiated phenotype: they produced less IL-2 but more IFN-γ, compared to CD28H-positive counterparts (Supplementary Figure  S7d) . Taken together, our data indicated that loss of CD28H in T cell defines as replicative senescence.
CD28H delivers a positive co-stimulatory signal to T cells
We first test whether CD28H could function as a possible co-signaling receptor on T cells. Similar to the CD28 family receptors, the intracellular domains of CD28H contain three tyrosines, whose phosphorylation could potentially play a crucial role in signal transduction. We took advantage of the well-known characteristics of agonistic CD28 mAb and constructed various CD28-CD28H chimeric molecules. HEK293T cells were transfected with these chimeric CD28H constructs and then treated with Pervanadate, an irreversible protein-tyrosine phosphatase inhibitor to block endogenous tyrosine phosphorylation. This transfection led to tyrosine phosphorylation of wild type (WT) CD28 and CD28-CD28H chimera but not CD28-CD28H Del mutants (Figure 3a ), indicating that tyrosines in the CD28H intracellular domain have the potential to be phosphorylated and therefore to mediate signal transduction. Further studies used site-directed mutagenesis to replace each tyrosine in the intracellular domain of CD28H with phenylalanine. These studies indicated that Y192 and Y222, but not Y197 of CD28H, could potentially be phosphorylated ( Figure  3b ). Confocal imaging analysis revealed that the CD28H protein was distributed on naïve T cell surface membrane, and seemed to co-localize with CD3. Interestingly, as CD3 redistributed upon T cell activation, CD28H also became concentrated in the synapse with CD3 without cross-linking of the CD28H receptor ( Figure 3c ). These results support a possible role for CD28H in the regulation of T cell receptor signaling events during activation.
We next directly tested whether signaling through CD28H could affect T cell function. We first measured the proliferative response to plated-bound anti-CD3 (OKT3) in the presence of CD28H mAb or control mAb (hamster anti-TNP mAb). As shown in Figure 3d , CD28H mAb co-immobilized with different concentrations of CD3 mAb greatly enhanced T cell proliferation compared with the control. The co-stimulatory effect of CD28H mAb was dose-dependent, and its co-stimulatory effect could be achieved even in the presence of a costimulatory CD28 mAb ( Figure 3e ). As a result, CD28H-co-stimulated human T cells produced higher levels of IL-2 as well as IFN-γ and IL-10 than the control mAb ( Figure 3f ). These results indicate that our CD28H mAb is capable of co-stimulating T cells in the presence of TCR signaling.
Co-signaling molecules could affect T cell proliferation through promoting the cell cycle or increasing survival 4, 27 . To distinguish these possibilities, we added BrdU to cultured T cells and evaluated the cell cycle progression and cell death by co-staining for BrdU and 7-AAD, respectively. As shown in Figure 3g , CD28H mAb treatment greatly increased T cells in S phase compared to the control mAb (24.9% vs 11.5%). However, crosslinking of CD28H did not help to prevent cell death (2.56% vs 1.17%). Thus, our data support the concept that CD28H signaling co-stimulates T cells through promoting the cell cycle in S phase.
We further tested the effect of CD28H mAb in vivo, using a xenograft model of graft versus host disease 21 . CD28H mAb was given on day 0 and day 2 after human T cell transfer. This treatment significantly accelerated human T cell division, as evidenced by CFSE dilution (Figure 4a ). In addition, T cells from CD28H mAb-treated mice gained more effector functions. As shown in Figure 4b , there were significantly more CD4+ T cells expressing membrane-bound CD40L and secreting effector cytokine IFN-γ in CD28H mAb-treated mice, compared with those from control mice. CD28H treatment increased the percentage of CD107a-positive CD8+ T cells, as well as IFN-γ-producing cells. Altogether, our results indicate that CD28H co-stimulation promotes T cell proliferation and differentiation.
Identification of B7-H5 as a ligand for CD28H
In an effort to identify its interacting partner, we first tested whether CD28H interacts with any known B7 family member. HEK293T cells were transiently transfected with individual known human B7 ligands and stained with CD28H protein by flow cytometry. We did not find any binding of CD28H protein to HEK293T cells expressing known B7 members (Supplementary Figure S8) .
By a high throughput screening of the receptor array containing over 2,300 transmembrane proteins 28 , we identified a binding candidate and named it B7 homolog 5 (B7-H5) ( Figure  5a ). B7-H5 was previously known as human endogenous retrovirus-H long terminal repeatassociating 2 (HHLA2) without an identified function 29 . Interestingly, this molecule has been noted as a new candidate for the B7 family based on a homolog search 30 . By comparing its protein sequence, we demonstrated its homology to other known human B7 ligand members (Figure 5b ). Therefore we assigned the gene a new name B7-H5. B7-H5 has three signature Ig domains (IgV-IgC-IgV) in its extracellular region. Interestingly, the first IgV domain of B7-H5, which presumably contains the receptor-binding domain, has the highest homology with other B7 family members (Supplementary Figure S9) . Notably, mice and rats do not have the ortholog for B7-H5, which is similar to the CD28H gene.
To validate the interaction between B7-H5 and CD28H, we generated mAbs to human B7-H5 by immunizing BALB/c mice with a B7-H5-Ig fusion protein. One B7-H5 mAb, clone 2D3, specifically bound B7-H5 transfected cells but not mock-transfected cells (Supplementary Figure S2b) . The receptor array screening results were confirmed by flow cytometry, as the CD28H-Ig fusion protein specifically bound to stable B7-H5 CHO transfectants but not to control CHO cells (Figure 5c left) . Importantly, inclusion of 2D3 was able to completely block this interaction (Figure 5c right) . Similarly, we transiently transfected HEK293T cells with CD28H and stained with B7-H5-Ig. B7-H5-Ig bound strongly to the HEK293T cells transfected with CD28H, but not to the control plasmid, further suggesting that B7-H5 binds specifically to CD28H (Figure 5d ). The direct interaction between B7-H5 and CD28H was also verified by Enzyme-linked immunosorbent assay (ELISA). As shown in Figure 5e , Biotin-labeled CD28H protein directly interacted with immobilized B7-H5 but not B7-H3 protein, and this binding could be completely blocked when the plate was pre-incubated with 2D3.
We also excluded the possibility that B7-H5 interacts with other CD28 family members. As shown in Figure 5f , B7-H5-Ig did not bind to any known CD28 family receptors other than CD28H. Furthermore, the receptor array screening using B7-H5-Ig as the bait identified CD28H as the only binding partner for B7-H5 in our Array library (Supplementary Figure  S10) . Therefore, the B7-H5/CD28H interaction represents a new independent pathway related to the classic B7/CD28 family.
The expression pattern of B7-H5
Early study by Northern blotting indicated that B7-H5 messenger RNA (mRNA) was enriched in peripheral organs 29 . By PCR, we detected abundant levels of B7-H5 mRNA in testis, colon, lung, kidney and pancreas while its transcript level was low in the small intestine, liver and skeletal muscle (Figure 6a) . In immune cells, the B7-H5 transcript was undetectable in T cells, while B cells, dendritic cells and macrophages contained abundant B7-H5 mRNA (Figure 6b) . No cell surface B7-H5 expression was detected on T, B, NK cells or monocytes freshly isolated from human PBMCs by 2D3 staining (Figure 6c) . However, substantial cell surface B7-H5 could be detected on monocyte-derived macrophages and could be further upregulated by poly (I:C) (Figure 6d ). Monocyte-derived dendritic cells expressed minimal levels of B7-H5 protein; however, incubation of dendritic cells with IFN-γ, poly I:C or heat-killed Listeria monocytogenes (HKLM), was capable of inducing B7-H5 expression while LPS had marginal effect (Figure 6d ). Our data suggest that B7-H5 is largely an inducible molecule on APCs responding to inflammation.
B7-H5/CD28H interaction co-stimulates human T cell responses
To test the potential function of B7-H5 on T cell activation, we incubated purified CD4+ human T cells with plate-coated B7-H5-Ig in the presence of anti-CD3 mAb to mimic TCR ligation. Similar to B7-1, immobilized B7-H5-Ig strongly promoted CD4+ T cell proliferation. B7-H5 played a co-stimulatory role because the B7-H5-Ig did not enhance T cell response in the absence of the anti-CD3 mAb (Figure 7a) . Furthermore, B7-H5 increased a variety of cytokine production, including IL-2, IFN-γ, TNF and IL-10 ( Figure  7b ). Addition of CD28H-Ig or a B7-H5 mAb (2D3) significantly reduced the co-stimulatory effect of B7-H5 (Figure 7c ), indicating that B7-H5 promotes the T cell response through CD28H on T cells.
To further evaluate the function of endogenous B7-H5/CD28H interaction on the T cell response, we stimulated human T cells with pre-activated allogeneic macrophages. The inclusion of 2D3 significantly reduced the allogeneic T cell proliferation (Figure 7d left) and IFN-γ secretion (Figure 7d right) . We further examined whether blockade of the B7-H5/ CD28H pathway could alleviate allogeneic T cell responses in vivo. Humanized NSG mice were challenged with allogeneic macrophages intraperitoneally. As shown in Figure 7e , administration of 2D3 significantly inhibited human T cell proliferation, based on Ki-67 staining. Taken together, our results support that endogenous B7-H5/CD28H interaction plays an important role in allogeneic T cell response.
B7-CD28 co-stimulation is known to activate the phosphoinositide 3-kinase (PI3K)-and serine-threonine kinase AKT-dependent signaling cascade and promote cellular proliferation and T cell activation 31, 32 . We activated human T cells with immobilized anti-CD3 and B7-H5 or control Ig proteins. As shown in Figure 7f , simultaneous cross-linking of TCR and B7-H5 induced AKT phosphorylation 30 min after stimulation, while TCR cross-linking alone induced minimal AKT phosphorylation. Importantly, inclusion of 2D3 prevented AKT activation, indicating that B7-H5 co-stimulation presumably utilizes the AKT pathway to promote T cell response.
CD28H ligation regulates antigen-specific T cell responses
We further evaluated the effects of CD28H-B7-H5 pathway in an antigen-specific T cell response. Purified human CD4+ T cells were labeled with CFSE, and cultured with autologous monocyte-derived dendritic cells pre-incubated with tetanus toxoid (TT). TT− specific T cell proliferation was strongly augmented when agonistic CD28H mAb was included in the culture to amplify CD28H signal on T cells (Figure 8a) . Inclusion of CTLA4-Ig, a fusion protein blocking B7-CD28 interactions, at the beginning of cell culture greatly inhibited T cell proliferation, even in the presence of agonistic CD28H mAb. Our results indicate that CD28H costimulation may be dependent on endogenous B7-CD28 interaction. We also noted a substantial enhancement of cytokine production by CD28H agonistic antibody, including IFN-γ, IL-5, IL-10, TNF-α and IL-17 ( Figure 8b ).
We also evaluated the role of this costimulatory interaction on TT-specific T cell response in vivo. In this model, NSG mice were transferred with human PBMCs together with autologous monocyte-derived dendritic cells, and were immunized with tetanus toxoid vaccine. Endogenous B7-H5/CD28H interaction appears to be important for the recall of TT-specific memory T cells because injection of the mice with B7-H5 blocking mAb 2D3 significantly inhibited TT vaccine-elicited T cell proliferation, as indicated by BrdU incorporation (Figure 8c ). Inoculation of CTLA-4Ig, a positive control, completely abrogated the TT vaccine-induced T cell proliferation. As a result, cytokines in the culture supernatant including IFN-γ, IL-5 and IL-10 were all substantially reduced by the 2D3 mAb (Figure 8d ). Taken together, our studies supported that the B7-H5/CD28H interaction plays an important role in the recall of memory T cells.
Discussion
In this study we describe a new cell surface molecular interaction between CD28H and B7-H5 with co-stimulatory functions for T cells. Similar to parental CD28 molecule, CD28H is constitutively expressed in naïve T cells and NK cells and transmits a co-stimulatory signal to T cells through AKT pathway. CD28H accumulates at the immunological synapse upon T cell activation without ligand binding, a feature shared by CD28 33 . In addition, CD28H appears to be a pan-T cell activator and co-stimulates T cells without bias to different subsets. It has been shown that repetitive stimulation of human CD4+ T cells will lead to permanent loss of CD28 on the cell surface, which is associated with T cell senescence 34 . Similarly, repeated stimulations of human T cells eliminate CD28H expression and the phenotypes of these CD28H-negative cells are similar to those ageing T cells. However, several major features distinguish this pathway from the classic B7/CD28 pathway. In contrast to B7-1 and B7-2, which are limited on professional APCs, B7-H5 could be found abundantly in peripheral tissues. In the context of these findings, the B7-H5/CD28H interaction appears to be critical for the co-stimulation of newly generated effector or effector/memory T cells in peripheral tissues in addition to lymphoid organs. Another important difference is that the B7-H5/CD28H interaction is not present in mice and rats. It is worthwhile to note that a recently identified B7-H2/CD28 interaction is also not found in mice 28 . Thus, these findings may warrant reassessment of the B7-CD28 co-stimulatory system in humans.
Unlike other known B7 members, the extracellular domain of B7-H5 contains three Ig domains rather than the two Ig domains, with an exception of two duplicated IgV-IgC in human B7-H3 35 . Its counter receptor, CD28H, also an Ig superfamily (IgSF) member, shares structural similarity with other CD28 family molecules. Neither B7-H5 nor CD28H bound other known B7 receptors or ligands respectively. In addition, CD28H does not bind B7-H5-negative APCs, such as monocytes or immature dendritic cells (Supplementary Figure S11) . Over 20 human tumor lines we examined, CD28H only bound three B7-H5-positive human cell lines. Inclusion of a B7-H5 blocking mAb completely abolished these bindings (Supplementary Table S1 and Supplementary Figure S11 ). All these suggest that B7-H5/ CD28H interaction represents an independent B7 pathway.
CD28H is constitutively expressed on all naive human T cells. However, a significant percentage of effector/memory T cells from human PBMCs lost CD28H expression. Though B7-H5 is expressed at relatively low levels on resting dendritic cells and macrophages, it could be upregulated in response to a variety of inflammatory stimuli. These data implicate that, in the presence of inflammation, CD28H could provide a positive signal during naive T cell priming. However, in contrast to the restricted expression of B7-1 and B7-2 to professional APCs, B7-H5 was abundantly found in peripheral non-hematopoietic organs, implying a preferential role for B7-H5 in peripheral tissues. As effector memory T cells reside in extra-lymphoid sites and provide fast-responding immune surveillance against infections and tumors, the presence of B7-H5 could provide a better immune microenvironment for the recall response of memory T cells [36] [37] [38] . However, excessive T cell response could also be destructive during autoimmune diseases and chronic infections. Under these conditions, the gradual loss of CD28H expression upon exposure to antigens would provide a self-protective mechanism to restrain the T cell response.
Taken together, our results describe a new co-stimulatory pathway, which is independent of other known B7 family members. Its potential involvement in human diseases, however, has yet to be elucidated. It is valuable to further investigate the B7-H5/CD28H pathway in patients with autoimmune diseases or cancer, which would ultimately reveal new potential therapeutic interventions.
Methods
Plasmids and fusion proteins
The plasmids for B7-H5 and CD28H full-length cDNA were purchased from the Open Biosystems Inc. (Huntsville, AL). They were cloned into the pcDNA3.1(−) vector by PCR. The extracellular domains of B7-H5 and CD28H were cloned and fused into pmIgV expression vectors containing the constant region of mouse IgG2a 39 . Fusion proteins were expressed by transiently transfecting HEK293T cells usingthe calcium phosphate precipitation method and fusion proteins were purified using a Protein A Sepharose column according to the manufacturer's instructions (GE Healthcare). To enhance the secretion of fusion protein, the native signal peptide of B7-H5 was replaced with the preprotrypsin signal peptide derived from the pCMV FLAG vector (Sigma, MO).
Antibodies
Mouse anti-human B7-H5 mAb (clone 2D3) was generated from a hybridoma derived from the fusion of SP2 myeloma with B cells from a mouse immunized with human B7-H5-Ig. Hamster anti-human CD28H mAb (clone 4-5) was generated from a hybridoma derived by fusion of SP2 myeloma with B cells from an Armenian hamster immunized with human CD28H-Ig 40 . Hybridomas was cultured in RPMI with 10% fetal bovine serum (FBS). Antibodies in supernatant were purified by Hitrap protein G affinity column (GE Healthcare).
Anti-human Ig and anti-mouse Ig FMAT blue antibody were purchased from Applied Biosystems (Foster City, CA). Control hamster IgG and hamster anti-mouse TNP were purchased from eBioscience. All other antibodies used in flow cytometry were purchased from BD Bioscience (San Jose, CA), eBioscience or biolegend. Rabbit anti-total AKT, and anti-phospho-AKT (Ser473) were purchased from Cell Signaling (Danvers, MA).
Screening of the receptor array
Plasmids containing over 2300 human transmembrane genes were placed individually into several 384-well plates at 60ng/well. Lipofectamine 2000 was added to each well and mixed with plasmids for 30 minutes. Ten thousand 293T cells were added subsequently to each well to perform transient transfection. Eight hours after transfection, 50ng human CD28H-Ig or B7-H5-Ig and 50ng anti-mouse Ig FMAT blue secondary antibody were added into each well. The plates were read twenty-four hours after transfection by the Applied Biosystems 8200 cellular detection system and analyzed by CDS 8200 software. Each plate has a well containing the Fc receptor as an internal positive control for transfection.
Chimeras and tyrosine mutants
The CD28-CD28H chimera, which contains the extracellular domains of CD28 but the transmembrane and intracellular domains from CD28H, was generated by PCR. The CD28-CD28H Ddel mutant with deleted intracellular domains was generated by PCR using CD28-CD28H as the template. Mutants for the three tyrosines (Y192, Y197 and Y222) in CD28H intracellular domain were made by changing respective tyrosine (Y) to phenylalanine (F). Double and triple tyrosine-to-phenylalanine mutations were further generated by using one primer pair to PCR with a single or double tyrosine-mutated template.HEK293T cells transfected with individual plasmid were incubated in the presence or absence of 100μM pervanadate for 10min. Cells were lysed for 30min in lysis buffer at 4 degrees and centrifuged at 14,000g for 10min. The supernatant was immunoprecipitated with 1μg CD28 mAb and 20μl of protein G-magnetic beads (Invitrogen). After being washed with lysis buffer three times, the pellets were boiled for 10min with 3X SDS-PAGE loading buffer and resolved on 10% polyacrylamide gels. After being transferred to nitrocellulose, blots were analyzed for phosphotyrosine using 4G10 (Millipore) or CD28 using biotinlated-anti-CD28 (R&D system).
Immunohistochemistry staining and flow cytometry analysis
Immunohistochemistry for CD28H was performed with CD28H mAb (clone 4-5) at a concentration of 5 μg/ml according to a standard protocol 41 . For cell surface staining and analysis by flow cytometry, cells were incubated with the indicated mAb for 30 min at 4°C, washed with buffer and analyzed. For intracellular cytokine analysis, T cells were restimulated with PMA plus Ionomysin in the presence of brefeldin A. The cells were then stained with indicated mAb to cell surface molecules, cytokine antibodies or control for 30 min at 4°C, fixed and permeabilized before analysis. For CD107a staining, PE-labeled CD107a and isotype control antibody was added during the culture.
T cell proliferation assay
Human peripheral mononuclear cells (PBMCs) from healthy donors were purchased from Research Blood Components (Brighton, MA). OKT mAb (anti-human CD3) was pre-coated in the 96-well plates at the indicated concentrations. B7-H5.Ig, anti-CD28H, B7-1 or control Ig at 5ug/ml were also immobilized in the wells. Human peripheral blood T cells were negatively selected and purified by a human pan-T cell selection kit or naïve human CD4 T cell selection kit (Miltenyi Biotec, Auburn, CA). T cells were added into each well at 2.5-3 ×10 5 per well and cultured for three days. In some experiments, co-stimulatory anti-human CD28 was added at the beginning of the culture. 3 H-thymidine (TdR) was added during the final six hours of culture. 3 H-TdR incorporation was counted with a MicroBeta Trilux liquid scintillation counter (Wallac).
Cytokine measurement
Supernatant from the T cell co-stimulation assays were collected. Human IFN-γ, IL-2 and IL-10 were detected by ELISA (BD PharMingen or eBioscience). In some experiments, cytokine levels in the supernatant were analyzed using a BD Cytometric Bead Array (CBA) Kit, according to the manufacturer's instructions.
Xenogeneic graft-versus-host disease model
Female NSG mice (Jackson Lab) were intraperitoneally transferred with 15~20 million human PBMCs or 10 million purified naïve CD4+ human T cells. On day 0 and 2, each mouse was inoculated peritoneally with 300μg control or CD28H mAb. 6 days after transfer, splenocytes were harvested. Human T cells were detected by staining for human CD45, CD3, and CD8. Splenocytes were restimulated in vitro with PMA plus ionomycin to detect IFN-γ or CD107a-producing cells. To monitor cell division, hPBMCs were labeled with CFSE before transfer. All mouse protocols were in accordance with NIH guidelines and were approved by the Animal Care and Use Committee of the Johns Hopkins University School of Medicine and Yale University School of Medicine.
Allogeneic T cell responses in a humanized mouse model
Human CD133 + CD34 + cells were purified from fresh umbilical cord blood and were transferred into sub-lethally irradiated neonates NOD-SCID Il2rg −/− (NSG) mice by intracardiac injection within the first 48 hours after birth. Reconstitution of the human immune system in the NSG mice was confirmed by examining human CD45+ cells in the mouse peripheral blood by flow cytometry 12 weeks post engraftment. Mice were adoptively transferred with two million allogeneic macrophages. At the same day, each mouse was inoculated with 500μg control or anti-B7-H5 (clone 2D3) mAb. Seven days later, mice were sacrificed and splenocytes were harvested. Human T cell subsets were detected by staining for human CD3 and CD8. Cellular proliferation was examined by intracellular staining of Ki-67.
Tetanus toxoid-specific human T cell response
For in vitro tetanus toxoid stimulation, Dendritic cells were incubated with 2μg/ml tetanus toxoid (List Biological Laboratories) overnight. After washed with culture medium, DCs were co-cultured with CFSE-labeled synergistic human PBMCs at 1:10 ratio for 7-10 days. Antibodies and fusion proteins were added from the beginning of culture. Cell division of human CD4+ T cells was examined by FACS for CFSE dilution. At the same time, cytokines in supernatant from the culture was checked by a human Th1/Th2/Th17 CBA Kit (BD Bioscience).
To study tetanus toxoid immunization in vivo, we intraperitoneally transferred 6~8 million human PBMCs along with 0.6 million synergistic dendritic cells into each NSG mouse. At the same time, each mouse was immunized with 1/30 dose of TENIVAC (0.5ml, Sanofi Pasteur). Mice were divided into three groups, and were treated with 250μg control Ig, 2D3 or CTLA4-Ig respectively. Seven days later, cells in the peritoneal were washed out by cold PBS, counted and restimulated with synergistic DCs pre-incubated with TT. BrdU was added from the beginning to record T cell proliferation. On day 7, supernatant was collected to check cytokine level, and cells were harvested to study T cell division by BrdU incorporation.
T cell lysate preparation and immunoblot
Purified human CD4 + T cells from healthy donors were activated with 1μg/ml immobilized anti-CD3 (OKT3) for 3 days, and rested for another 3 days in the presence of 50IU/ml rhIL-2. T cells were subsequently harvested and added into 96 well plates pre-coated with 0.01μg/ml anti-CD3 plus 10μg/ml B7-H5-Ig or control Ig proteins. In some wells, anti-B7-H5 (2D3) or control Ig were included in the culture. Cells were harvested at different time points as indicated. Cell lysates were prepared. 100μg total protein per sample was loaded and separated by 12% SDS-PAGE. The amount of phosphorylated AKT protein was determined by immunoblotting with Ser473 phospho-specific AKT antibodies. Membrane was subsequently striped and reprobed with antibodies against total AKT. 
